Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84)

(2015) M. L. Alva et al.   DIABETIC MEDICINE

Cost-Effectiveness Analysis of Exenatide Once-Weekly Versus Dulaglutide, Liraglutide and Lixisenatide for the Treatment of Type 2 Diabetes Mellitus: An Analysis from the UK NHS Perspective

(2015) M Charokopou et al.   VALUE IN HEALTH

Evaluating the Cost-Effectiveness of GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the UK

(2015) D Ashley et al.   VALUE IN HEALTH

Cost-effectiveness of once daily GLP-1 receptor agonist lixisenatide compared to bolus insulin both in combination with basal insulin for the treatment of patients with type 2 diabetes in Norway

(2015) Pernilla Huetson et al.   JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece

(2014) Charalampos Tzanetakos et al.   BMC HEALTH SERVICES RESEARCH

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Liraglutide: A Review of Its Use in Adult Patients with Type 2 Diabetes Mellitus

(2014) Lesley J. Scott   DRUGS

Diminishing marginal disutility of hypoglycaemic events: results from a time trade-off survey in five countries

(2014) Jørgen T. Lauridsen et al.   QUALITY OF LIFE RESEARCH

Validation of the IMS CORE Diabetes Model

(2014) Phil McEwan et al.   VALUE IN HEALTH

Review of Utility Values for Economic Modeling in Type 2 Diabetes

(2014) Amélie Beaudet et al.   VALUE IN HEALTH

Self-Reported Frequency and Impact of Non-Severe Hypoglycaemia in Insulin-Treated Adults in the UK

(2014) B. Chubb et al.   VALUE IN HEALTH

Glucagon-Like Peptide-1 Receptor Agonist Treatment Patterns Among Type 2 Diabetes Patients in Six European Countries

(2014) Victoria Divino et al.   Diabetes Therapy

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes

(2013) H. J. Lambers Heerspink et al.   DIABETES OBESITY & METABOLISM

Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries

(2013) Marc Evans et al.   Health and Quality of Life Outcomes

The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m2in Spain

(2013) Tiago Fonseca et al.   JOURNAL OF MEDICAL ECONOMICS

Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs

(2012) N. Hex et al.   DIABETIC MEDICINE

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus

(2011) M. J. Davies et al.   DIABETIC MEDICINE

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

Cost-effectiveness of insulin analogues for diabetes mellitus

(2009) C. G. Cameron et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

(2009) B. Zinman et al.   DIABETES CARE

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Clinical and cost-effectiveness analysis of an open label, single-centre, randomised trial of spinal cord stimulation (SCS) versus percutaneous myocardial laser revascularisation (PMR) in patients with refractory angina pectoris: The SPiRiT trial

(2008) M T Dyer et al.   Trials